Investor News: Lawsuit against Array Biopharma Inc (NASDAQ:ARRY) alleges Misleading Statements

An investor in NASDAQ:ARRY shares filed a lawsuit against Array Biopharma Inc over alleged violations of Federal Securities Laws.

Investors in shares of Array Biopharma Inc (NASDAQ:ARRY) should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

The plaintiff claims that between December 16, 2015 and March 17, 2017, the defendants issued materially false and/or misleading statements and/or failed to disclose that Array’s NEMO study failed to show sufficient clinical benefit of the binimetinib NDA in use for patients with NRAS-mutant melanoma, that it was aware that this lack of supporting data would not be sufficient to receive FDA approval of binimetinib in use for patients with NRAS-mutual melanoma, and that as a result of the foregoing, Array’s public statements were materially false and misleading at all relevant times

Those who purchased shares of Array Biopharma Inc (NASDAQ:ARRY) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com